ArticleFrontiers in cardiovascular medicine2026
Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In-stent restenosis (ISR) remains a significant clinical challenge despite advances in drug-eluting stent (DES) technology. Although current guidelines recommend drug-coated balloon (DCB) angioplasty or repeat DES implantation for DES-ISR, real-world data comparing DCB with newer-generation ultrathin-strut sirolimus-eluting stents (SES) are limited. Methods: This retrospective, single-center study included consecutive patients with stable angina who underwent treatment for DES-ISR using either a paclitaxel-coated DCB or an ultrathin-strut SES between January 2015 and May 2025. The primary outcome was target-lesion revascularization (TLR). Secondary endpoints included major adverse cardiac events (MACE), defined as a composite of all-cause mortality, myocardial infarction, stroke, and TLR. Time-to-event analyses were performed using Kaplan-Meier methods and Cox proportional hazards regression. Results: A total of 205 patients were included (DCB, Conclusions: Ultrathin-strut SES was associated with lower TLR and MACE rates compared with DCB in non-focal DES-ISR, whereas outcomes were comparable in focal ISR. These findings highlight the importance of lesion characteristics and support a tailored approach to ISR management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.